department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Blueprint Medicines Corp · pharmadog

PUBLIC COMPANY

Blueprint Medicines Corp

updated 1mo ago

community read0 votes

pipeline

4

marketed

2

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(4)

pipeline depth4 products

1Phase 21Phase 32Marketed

Gastrointestinal Stromal Tumor (GIST)

Systemic Mastocytosis

Chronic Inducible Urticaria

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Blueprint Medicines Corp jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

Oncology3 Dermatology1 NSCLC1

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosiscompletedn=107
—An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)recruitingn=150
—A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germanyrecruitingn=80
—Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populationsrecruitingn=450
phase3(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosisrecruitingn=534
phase1A Study of Elenestinib in Healthy Adult Female Participantscompletedn=20
phase2Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)recruitingn=105
phase2Study of BLU-808 in Allergic Rhinoconjunctivitiscompletedn=21

more trials →